My Cart [ 0 ]
Home > Cell Biology > Stable Cell Lines > Humira Biosimilar Stable Cell Line

Humira Biosimilar Stable Cell Line

Adalimumab, Anti-TNF alpha Human Monoclonal Antibody

Catalog No. Product Name Size List Price (US$) Quantity
C003 Humira Biosimilar Stable Cell Line 1 package Request

Adalimumab (trade name Humira, AbbVie), the first fully human monoclonal antibody drug approved by FDA, binds to TNFα, inactivates TNF receptors, and downregulates the inflammatory reactions associated with a variety of autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and juvenile idiopathic arthritis.

Mainly produced by activated macrophages (M1), Tumor necrosis factor (TNF, cachexin, cachectin, tumor necrosis factor alpha, TNFα) plays important roles in the regulation of immune cells. As a member of a group of cytokines that stimulate the acute phase reaction, TNF is involved in systemic inflammation and able to induce fever, apoptotic cell death, cachexia, inflammation, and to inhibit tumorigenesis and viral replication and respond to sepsis via IL1 & IL6 producing cells. Dysregulation of TNF expression could have serious impact in a variety of human diseases including Alzheimer's disease, cancer, major depression and inflammatory bowel disease.

C003: Humira Biosimilar Stable Cell Line (CHO)

The yield of Humira biosimilar from the CHO stable cell line was above 2.0 g/L in a 50 liter manufacturing.

The Humira biosimilar stable cell line alone can be transferred alone or together with the technology of process development and/or antibody purification.

Syd Labs also provides the following anti-TNF antibody biosimilar stable cell line:
Remicade Biosimilar Stable Cell Line

Related Links

See our Privacy Policy